Using aspirin to prevent colorectal cancer
Official title: Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer
Run by Instituto de Investigación Sanitaria Aragón · NCT03957902 · Data updated 2026-11-12
This study is testing if different doses of aspirin can help prevent colorectal cancer by looking at how it affects certain markers in the body.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 79 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Instituto de Investigación Sanitaria Aragón Academic / other |
| Locations | 1 site (Zaragoza, Zaragoza) |
| Status | Recruiting |
| Started | May 6, 2019 |
| Main results expected | May 2025 |
| Study ends | June 2025 |
| Registry record updated | February 27, 2025 |
| Trial ID | NCT03957902 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 80 who have received a recent diagnosis of rectal or colon cancer.
✕Probably not a fit
Patients with allergies to aspirin or NSAIDs, those requiring immediate neoadjuvant treatment, or those with certain gastrointestinal conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of acetylsalicylic acid (ASA) as a potential chemoprevention therapy for colorectal cancer (CRC). It aims to assess the direct biomarkers of aspirin action by comparing the effects of different doses of ASA on the cyclooxygenase (COX) isoenzyme COX-1 in the colorectal mucosa and platelets. The study will also measure levels of prostaglandin E2 and other biomarkers related to inflammation and tumorigenesis in CRC patients. The goal is to identify the appropriate dose and target population for effective CRC prevention.
Why it matters
Potential benefit: If successful, this study could lead to a targeted approach for preventing colorectal cancer in at-risk patients using aspirin.
How similar studies have gone: Other studies have explored the use of aspirin for colorectal cancer prevention, showing promising results, but this specific approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 \< 80 years old * recent diagnosis (\< 48h) of rectum or colon cancer, established by endoscopy and later confirmed by anatomo-pathologic study * normal coagulation values and biochemical vales without clinically significant deviations that, at the discretion of the investigator, may interfere with the study procedures Exclusion Criteria: * Allergy to ASA or to any other NSAID. * Rectal cancer requiring neoadjuvant treatment within the two weeks following the beginning of ASA treatment. * Previous use of ASA, NSAIDs, antiplatelet agents, corticosteroids or misoprostol within the 15 days prior to diagnosis and/or anticipation of need for treatment with any of these drugs during the study period. History of peptic ulcer disease or active peptic ulcer or any other gastrointestinal disease that may be considered a contraindication to the use of ASA, without the concomitant use of proton pump inhibitors. * Diagnosis of bleeding disorders. * Diagnosis of cancer (excluding non-melanoma skin cancer) within the previous 3 years. * Conditions supposing serious comorbidity, excluding diabetes, and including respiratory, cardiac, hepatic and renal diseases. * Active smoking. * Pregnancy or breastfeeding. * History of drug or alcohol abuse.
Where it's running
-
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Zaragoza, Spain Recruiting
Study contacts
- Principal investigator: Ángel Lanas Arbeloa, MD — Instituto de Investigación Sanitaria Aragón
- Study coordinator: Ángel Lanas Arbeloa, MD
- Email: angel.lanas@gmail.com
- Phone: 0034976765786
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.